It certainly isn't looking likely. We really need to see at least one CR in this next data set. At the very least more MRD patients turning MRD-. Even if we do though I just don't know that it will be enough to bring SP over $1. Aside from that data the only other things I can see helping out the SP are the initiation of the lymphoma trial and non-dilutive funding.
If they plan on having a lymphoma readout by the end of next year that trial needs to start ASAP. The early lymphoma data was the best of all indications tested in the BCM trials so it's not surprising that this trial would bring some excitement. The IND acceptance brought huge volume of almost 100M over 3 days. I have to assume more trial progress will bring in more volume. Will the SP hold is the big question.
I still fully expect them to dilute us all to hell but the company has given some indication they think they can access some non dilutive funding. If that really is a possibility then now is the time to do whatever it takes to make it happen. If they can get more funding without diluting shareholders and it's enough to fund the company past the end of next year then I do believe that would be enough to bring the SP over $1. I wouldn't hold out much hope for this though.
News 
Market Data 
Discover 
